£119.99

Pediatric Renal Transplantation: Protocols & Controversies (Renal and Urologic Disorders)

Price data last checked 25 day(s) ago - will refresh soon

View at Amazon

Price History & Forecast

Last 66 days • 66 data points (No recent data available)

Historical
Generating forecast...
£119.99 £113.99 £116.39 £118.79 £121.19 £123.59 £125.99 24 January 2026 09 February 2026 25 February 2026 13 March 2026 30 March 2026

Price Distribution

Price distribution over 66 days • 1 price levels

Days at Price
66 days 0 17 33 50 66 £120 Days at Price

Price Analysis

Most common price: £120 (66 days, 100.0%)

Price range: £120 - £120

Price levels: 1 different prices over 66 days

Description

The role of immunosuppression is essential to maintain the integrity of a renal transplant by preventing acute rejection. Among adult patients with solid organ transplants, standard immunosuppression does not vary among the major transplant centres in the USA and Europe, and consists of corticosteroids, calcineurin inhibitors and mycophenolic acid. However, children with renal transplants are more susceptible than adults to suffer adverse events related to this standard protocol, including short stature, nephrotoxicity, lymph proliferative disease and infections. For this reason, paediatric nephrologists have explored alternatives to standard immunosuppression while still maintaining acceptable graft outcomes. This book will explore this theme, which will include several chapters that present alternative immunosuppression protocol, in addition to other chapters that address challenging and controversial issues in paediatric renal transplantation. The first three chapters will describe immunosuppression protocols which may have specific benefits in children with renal allografts compared to standard regimens in adults. This includes the use of steroid-avoidance, which obviates many of the problems associated with corticosteroid use in children especially short stature and obesity. Secondly, the mTOR inhibitor Sirolimus is thoroughly discussed, including the potential benefits of this agent because of its lack of nephrotoxicity and possible anti-neoplastic properties. Lastly, induction therapy with Alemtuzumab is described, including recent studies that suggest that this agent may have definite benefits in children compared to standard induction with anti-thymocyte globulin.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
01 December 2014
Listed Since
17 October 2014

Barcode

No barcode data available